Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
ESTROSTEP FE SUMMARY
(Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets*)
ESTROSTEP® Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. ESTROSTEP Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each white triangle-shaped tablet contains 1 mg norethindrone acetate [(17 alpha)-17-(acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each white square-shaped tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each white round tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each tablet also contains calcium stearate; lactose; microcrystalline cellulose; and starch.
ESTROSTEP Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
ESTROSTEP Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. ESTROSTEP Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months.
Media Articles Related to Estrostep Fe (Norethindrone / Estradiol / Norethindrone / Estradiol / Norethindrone / Estradiol)
New technology combining contraception, HIV and herpes simplex virus-2 prevention
Source: HIV / AIDS News From Medical News Today [2013.11.14]
CONRAD Head of drug delivery, Meredith Clark, PhD, presented preclinical data on a new intravaginal ring that provides contraception as well as HIV-1 and HSV-2 prevention at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas.
Hormone levels in women using contraception affect nerve activity involved in vessel constriction
Source: Endocrinology News From Medical News Today [2013.11.10]
After menopause, women's levels of estrogen and progesterone fall. Their formerly lower risk for heart disease equals, even surpasses, men's risk. One possible contributing explanation for the change in risk is that sex hormones affect the sympathetic nervous system (SNS), which controls constriction of blood vessels and participates in the fight or flight response.
Contraception needed 3 weeks after giving birth, new mums warned
Source: Fertility News From Medical News Today [2013.10.23]
Fertility can return much more rapidly than many women assume after giving birth, and myths still abound about what contraception can and can't be used while breastfeeding.
White House Unveils Final Plan on Coverage for Contraception
Source: MedicineNet Birth Control Specialty [2013.07.01]
Title: White House Unveils Final Plan on Coverage for Contraception
Category: Health News
Created: 6/28/2013 2:36:00 PM
Last Editorial Review: 7/1/2013 12:00:00 AM
Published Studies Related to Estrostep Fe (Norethindrone / Estradiol / Norethindrone / Estradiol / Norethindrone / Estradiol)
Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study. [2007.09]
OBJECTIVE: This study sought to determine whether combined continuous ethinyl estradiol and norethindrone acetate, a postmenopausal hormone therapy (HT) combination designed to have fewer side effects than cyclical therapies and therapies using medroxyprogesterone acetate (MPA), could improve vascular endothelial function in postmenopausal women with risk factors for cardiovascular disease (CVD)... CONCLUSIONS: In this older postmenopausal population with at least one cardiovascular risk factor, treatment with combined continuous ethinyl estradiol and norethindrone acetate failed to improve vascular endothelial function. The agent's proinflammatory effect or subclinical atherosclerosis in this population may have contributed to this finding.
HT update: spotlight on estradiol/norethindrone acetate combination therapy. 
Abstract: The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman... The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.
A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. 
AIM: This multicenter, open-label, single-arm study evaluated subject satisfaction and improvements in menopausal quality of life among menopausal women using the CombiPatch transdermal system consisting of 17beta-estradiol 0.05 mg plus norethindrone acetate 0.14 mg in a matrix patch formulation... CONCLUSIONS: The results of this study compare favorably with previous placebo-controlled studies of transdermal hormone therapy in managing menopausal signs and symptoms. Furthermore, quality of life was significantly improved by the transdermal hormone therapy system, and both subjects and physicians reported high levels of satisfaction. Copyright 2005 S. Karger AG, Basel
Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. [2002.04.15]
OBJECTIVE: To determine the effects of nevirapine (NVP), a nonnucleoside reverse-transcriptase inhibitor of HIV-1 and P450 inducer, on the pharmacokinetics (PK) of ethinyl estradiol (EE)/norethindrone (NET), a widely used oral contraceptive, and to assess the effects of EE/NET on the steady-state PK of NVP... CONCLUSION: Oral contraceptives should not be the primary method of birth control in women of child-bearing potential who are treated with NVP.
Clinical Trials Related to Estrostep Fe (Norethindrone / Estradiol / Norethindrone / Estradiol / Norethindrone / Estradiol)
Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation [Recruiting]
The purpose of this research study is to gain a better understanding of the changes that may
occur in the breast when a woman uses an oral contraceptive (birth control pill). Some
research indicates that women who use birth control pills with lower amounts of estrogen (a
hormone in the birth control pill) may have lower breast cell growth than women who use
birth control pills with a higher amount of estrogen; this research will examine that in
detail. This research will also test whether the results found in HS-07-00269 can be
Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) [Recruiting]
The purpose of this study is to assess the contraceptive efficacy of a nomegestrol acetate +
17ß-estradiol (NOMAC-E2) combined oral contraceptive (COC) in healthy, sexually-active
American women at risk for pregnancy. Vaginal bleeding patterns of women taking NOMAC-E2
will be assessed and compared to those of women taking a norethisterone acetate + ethinyl
estradiol (NETA-EE) COC. The safety of NOMAC-E2 will also be assessed.
Participants will be randomized to receive either NOMAC-E2 or NETA-EE in a 3: 1 ratio.
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 2 ratings/reviews, Estrostep FE has an overall score of 9. The effectiveness score is 10 and the side effect score is 9. The scores are on ten point scale: 10 - best, 1 - worst.
Estrostep FE review by 29 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || contraceptive|
|Dosage & duration:|| || not sure (dosage frequency: daily) for the period of 8 years|
|Other conditions:|| || no conditions|
|Other drugs taken:|| || none|
|Benefits:|| || this drug claims 99.9% accuracy when administered daily with very little side effects, have been using for several years with no weight gain and no accidents. the packaging is simple, easy and convenient.|
|Side effects:|| || no side effects that i could recognize, pretty common.|
|Comments:|| || dosage is a daily administration, not complex. pretty convenient.|
Estrostep FE review by 27 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || oral contraceptive|
|Dosage & duration:|| || 1 pill a day taken everyday for the period of 4 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || this birth control pills helps your skin if u are someone who breaks out often |
|Side effects:|| || none really but i have increased pms symptoms around 2 weeks beforre my period etc.. certain food cravings, fatigue, muscle weakness. also lost weight from this pill as it suppresses my appetite|
|Comments:|| || one pill a day preferably at the same time every day|
Page last updated: 2013-11-14